BIRC5 and Erythema: Although AVA vaccination is considered safe, with mild injection site reactions most commonly reported, the potential development of adverse events increases with the multiple doses required.5,6 Subcutaneous delivery of 0.25–0.1 mL DPX in humans, when formulated with cancer immunogen survivin, causes minimal to mild induration and erythema at the injection site in a majority of patients.16 This same delivery format was recently used for testing DPX-RSV, a respiratory syncytial formulation, in humans.